Background and aims: Interleukin 26 (IL-26), a novel IL-
Interleukin 26 (IL-26), initially named AK155, was originally identified by subtraction hybridisation coupled with representational difference analysis as a gene upregulated in human T cells following infection with herpesvirus saimiri (HVS), with the capacity to transform these cells in culture. 1 The IL-26 protein has 24.7% amino acid identity and 47% amino acid similarity to human IL-10. IL-26 is a member of the IL-10-like cytokine family composed of cytokines with limited homology to IL-10, including IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A, IL-28B and IL-29. IL-28A/B and IL-29 are also known as interferon ls (IFNls). IL-26 signals through a novel receptor complex consisting of the transmembrane proteins IL-20R1 and IL-10R2. 2 In addition to cytokine-specific ligandbinding chains, IL-22, IL-26, IL-28A/B and IL-29 use a common second receptor chain (IL-10R2) for assembling their active receptor complexes and signalling.
The IL-26 gene is located on chromosome 12q14 in a cluster where IFNc and IL-22 are also positioned. IL-26 forms homodimers similarly to IL-10.
1 IL-26 was originally described as a gene upregulated upon HVS infection in T cells 1 but could also be detected in unstimulated fresh peripheral blood cells of healthy donors by reverse transcription-PCR (RT-PCR) analysis. 1 Although the IL-10 transcript was detected in most cell lines of T or B cell lineage, the IL-26 transcript was rather specific for T cells. In another study, under basal conditions no IL-26 mRNA could be detected in monocytes, natural killer (NK) cells or B and T cells. 3 Its expression could be induced only in NK cells and T cells upon stimulation with IL-2/IL-12 and anti-CD3 monoclonal antibody, respectively. 3 This induction of IL-26 mRNA was observed specifically in activated memory cells (CD4 + ; CD45RO + ) and during polarisation toward type 1 T helper (Th1) cells. 3 A recent, preliminary study with in vitro differentiated T cells derived from healthy human blood donors suggests that Th17 cells also express IL-26 following stimulation with IL-23. 4 Th17 cells are a newly discovered subset of inflammatory T cells 5 that differentiate in humans under the influence of IL-1b, IL-6, IL-21 and IL-23. 6 They are characterised by the expression of the transcription factor RORct 7 and the IL-23 receptor (IL-23R). 8 They produce a specific pattern of cytokines and chemokines such as IL-17A, IL-17F, IL-21, IL-22 and CCL20. 4 9 10 Th17 cells contribute to the pathogenesis of many inflammatory autoimmune diseases such as multiple sclerosis or rheumatoid arthritis (reviewed in Furuzawa-Carballeda et al 11 ) and inflammatory bowel disease (IBD). 12 13 Recent findings demonstrate that a heterodimer consisting of IL-20R1 and IL-10R2 functions as the IL-26 receptor. 2 14 This receptor complex is expressed particularly in epithelial cells such as keratinocytes and colonic epithelial cells. 14 However, there is currently very limited information on the biological functions of IL-26. Interestingly, both IL-22 and IL-26 have been identified outside of mammals, and their organisation and synteny demonstrate that this cluster of cytokines is well conserved during evolution. 15 However, in contrast to IL-22, no murine IL-26 homologue has been described so far, limiting the experimental opportunities to study the phenotypic consequences of IL-26 gene knockout and IL-26-mediated functions in murine models in vivo. Moreover, there are no studies on the effects of IL-26 in human disease published so far.
Given the IL-26 receptor expression in colonic epithelial cells 14 and our recent findings on the important role of other IL-10-like cytokines such as IL-22, IL-28A and IL-29 in the regulation of intestinal epithelial cells (IECs) 16 17 and hepatic cells, [18] [19] [20] we aimed to analyse in this study signal transduction pathways and specific biological functions mediated by IL-26 in IECs. Recently, we demonstrated that the IL-10-related cytokine IL-22, another Th1 and Th17 cytokine sharing the IL-10R2 subunit with IL-26 for signalling, is upregulated in intestinal inflammation and modulates intestinal barrier function. 16 Therefore, we focused in this study on the role of IL-26 in IECs and in IBD.
MATERIALS AND METHODS Reagents
The following antibodies were used in this study: anti-IL-26 and anti-IL-20R1 (R&D Systems, Minneapolis, Minnesota, USA), anti-IL-10R2 (Acris Antibodies, Herford, Germany), anti-RORct (Abcam, Cambridge, UK), anti-pSTAT1 (BD Transduction Laboratories, Franklin Lakes, New York, USA), anti-pSTAT3 (Upstate Biotechnology, Lake Placid, New York, USA), anti-STAT1 and anti-STAT3 (Santa Cruz Biotechnology, Santa Cruz, California, USA). Antibodies against phosphorylated extracellular signal-regulated kinase (ERK)-1/2 (Thr183/ Tyr185), phosphorylated stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK; Thr183/Tyr185) and phosphoAkt (Ser473) were purchased from Cell Signaling (Beverly, Massachusetts, USA). Anti-ERK-1/2, anti-SAPK/JNK and antiAkt antibodies were also from Cell Signaling. Horseradish peroxidase (HRP)-linked antirabbit and antigoat secondary antibodies were purchased from Amersham (Arlington Heights, Illinois, USA) and Santa Cruz Biotechnology. Secondary antibodies for immunohistochemistry (AlexaFluor 488 or AlexaFluor 546 coupled and peroxidase coupled) were from Invitrogen (Karlsruhe, Germany) and Dako (Hamburg, Germany). Fluorescein isothiocyanate (FITC)-conjugated antigoat antibody was from Sigma-Aldrich (Taufkirchen, Germany) and antirabbit Cy-2 antibody was from Jackson Immuno Research (Suffolk, UK). Recombinant human IL-26 was obtained from R&D Systems.
Cell culture
The human colorectal cancer-derived IEC lines SW480, SW620, Caco-2, HT-29, HCT116, T84 and DLD-1 were obtained from the American Type Culture Collection (Rockville, Maryland, USA). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 100 IU/ml penicillin, 100 mg/ml streptomycin and 10% heat-inactivated fetal calf serum (FCS) from PAA (Pasching, Austria) in a humidified 5% CO 2 atmosphere at 37uC.
Reverse transcription-PCR
RT-PCR was performed as previously described. 21 Briefly, total RNA was isolated using Trizol reagent (Invitrogen). A 2 mg aliquot of DNase-treated total RNA was reverse transcribed using the Qiagen Omniscript RT kit (Hilden, Germany). To control for genomic contamination, an identical parallel PCR was performed containing starting material that had not been reverse transcribed. The primers for the PCRs are shown in table 1. The specificity of the PCR products was verified by sequencing.
Quantitative PCR
Real-time PCR was performed with a Rotorgene RG-3000 cycler (Corbett Research, Sydney, Australia) using the Quantitect SYBR Green PCR Kit from Qiagen following the manufacturer's guidelines. Oligonucleotide primers (table 1) were designed not to amplify genomic DNA, according to the published sequences. The expression of each mRNA was normalised to b-actin expression in the respective cDNA preparation.
Immunohistochemistry and immunocytochemistry
Peroxidase staining of paraffin-embedded tissue slides was performed using standard protocols. Briefly, after deparaffinisation and demasking of antigens, endogenous peroxidases were blocked with H 2 O 2 . Slides were blocked with 10% normal serum and were incubated with avidin and biotin. Following incubation with the primary antibody overnight at 4uC, slides were incubated with the secondary, biotin-conjugated antibody. Next, they were incubated with HRP-streptavidin, followed by incubation with the peroxidase substrate 39-diaminobenzidine (DAB). Slides were counterstained with haematoxylin. Double immunofluorescent staining (anti-RORct and anti-IL-26) of colonic tissue was performed on paraffin-embedded tissue. Following deparaffinisation, tissue was fixed for 1 min in a mixture of ice-cold acetic acid and methanol (1:1). Slides were washed with Tris-Tween and were blocked for 1 h with normal serum. The first primary antibody (anti-RORct) was incubated overnight at 4uC and the secondary, fluorochrome-coupled antibody was incubated for 1 h at room temperature. After washing, incubation with the second primary antibody (anti-IL-26) and secondary antibody was performed in the same way.
Immunofluorescence staining of HT-29 cells was performed as described previously. 22 Signal transduction experiments, protein isolation, gel electrophoresis and immunoblotting
The signal transduction experiments were performed in overnight serum-starved IEC lines as indicated. Cells were stimulated with 100 ng/ml IL-26, unless indicated otherwise. This concentration was based on pilot experiments demonstrating a significantly greater effect of 100 ng/ml IL-26 for the activation of certain kinases than lower concentrations. Cells were solubilised in lysis buffer 16 for 20 min and lysates were cleared by centrifugation at 10 000 g for 20 min. The protein concentration of each sample was quantified by the Bradford method.
Immunoblotting was performed as previously described. 23 
Enzyme-linked immunosorbent assay
The BD OptEIA Human IL-8 Elisa Kit II (BD Biosciences, Bedford, Massachusetts, USA) was used for quantification of IL-8 release according to the manufacturer's instructions.
IL-26 immunoluminometric assay (ILMA)
Ninety-six-well plates (Nunc Maxisorb, Nunc, Wiesbaden, Germany) were incubated with a 1:1000 dilution of a monoclonal anti-IL-26-antibody for 7 days at 4uC. After blocking with 2% non-fat milk for 1 h at room temperature, the plates were incubated with serum samples and different dilutions of recombinant human IL-26 overnight at 4uC. Following incubation with a biotinylated polyclonal IL-26 antibody, neutravidin-HRP was added. Femtoglow (Michigan Diagnostics, Troy, Michigan, USA) was used as a chemoluminescent substrate and luminescence was measured in a microplate luminometer (Orion II, Berthold Detection Systems, Pforzheim, Germany).
Cell proliferation assay
HT-29 cells were seeded onto 96-well plates at a density of 5000 cells/well and grown for 1 day. After starvation in serum-free medium overnight, the cells were incubated with or without IL-26 (10 and 100 ng/ml) in medium containing 0.1% FCS for 48 h. Cell proliferation was determined using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wisconsin, USA) according to the manufacturer's instructions. Relative means (SEM) from three independent experiments are shown.
Apoptosis assays
Apoptosis assays were performed as described previously. 24 For induction of TRAIL (tumour necrosis factor-related apoptosisinducing ligand)-mediated apoptosis, TRAIL at a concentration of 100 ng/ml was used, and for CD95-mediated cell death, ligandspecific anti-APO-1 monoclonal antibody at concentrations of 500 and 1000 ng/ml was used. Cells were incubated for 24 h with the respective ligands and with or without IL-26 (10 or 100 ng/ml). Cells were harvested and were lysed in hypotonic lysis buffer (0.1% sodium citrate and 0.1% Triton X-100) containing 50 mg/ml propidium iodide, and were incubated at 4uC overnight. The nuclei were then analysed for DNA content by flow cytometry.
Colonic biopsies
All participating patients with IBD were recruited by the IBD center of the University-Hospital Munich-Grosshadern (Germany) and gave written, informed consent prior to biopsy sampling. The study was approved by the Ethics Committee of the Medical Faculty of the University of Munich. Biopsies were taken from patients with Crohn's disease and ulcerative colitis undergoing diagnostic colonoscopy. Patients with indeterminate colitis were excluded from the study. Demographic and clinical data were recorded by analysis of patient charts and a detailed questionnaire including an interview at the time of enrolment. The demographic data are summarised in table 2. The diagnosis of Crohn's disease or ulcerative colitis was determined according to established guidelines based on endoscopic, histopathological and radiological criteria.
From each patient, four biopsies were collected: two from macroscopically non-inflamed sites and two from macroscopically inflamed mucosa. IL-26 and IL-8 mRNA levels were measured in each individual biopsy. For quantification, the average IL-26 and IL-8 mRNA expression of the two non-inflamed biopsies was compared with the average expression in the two inflamed biopsies (all normalised to b-actin expression). In addition, IL-22 mRNA levels of these biopsies were available from a previous study 16 and were included in the correlation analysis.
Statistical analysis
Statistical analysis was performed using two-tailed Student t test. A p values ,0.05 was considered as significant. Measured values that differed from the means by more than four times the standard deviation were considered as outliers and were not included in the statistical analysis.
RESULTS

IECs express the IL-26 receptor complex
To utilise a cell system to study this ligand-receptor system, we first (fig 3A) and-to a lesser degree-SAPK/JNK kinases ( fig 3B) were transiently activated by 100 ng/ml IL-26. Moreover, IL-26 induced phosphorylation of Akt ( fig 3C) . The maximum ERK, SAPK/JNK and Akt activation was 15 min after cytokine stimulation (fig 3D) , whereas the maximal STAT1/3 phosphorylation levels were already reached 10 min after IL-26 stimulation ( fig 2C) .
IL-26 decreases proliferation but does not influence apoptosis in IECs
Recently, we demonstrated that activation of ERK MAP kinases, Akt and STAT proteins following stimulation with chemokines or IL-22 mediates IEC proliferation, 16 
IL-26 increases expression of proinflammatory cytokines
After demonstrating that the IL-26 receptor complex is functional in IECs, we next examined transcriptional targets of this cytokine. Previously, we identified SOCS-3 as a STAT1/ 3-dependent gene. 27 Therefore, we analysed SOCS-3 mRNA levels in IECs stimulated with IL-26. 
IL-26 mRNA expression is increased in the inflamed colonic mucosa of patients with Crohn's disease
Since we established that IL-26 upregulates the expression of proinflammatory cytokines in IECs, we next analysed by real-time PCR its expression in intestinal inflammation in vivo. This analysis included a total of 88 biopsy samples taken from 22 different patients with IBD (Crohn's disease: n = 12; ulcerative colitis: n = 10). The demographics of these patients and the anatomic segment of the biopsy sampling are summarised in table 2.
Ileal and colonic biopsies were taken from sites with endoscopically (macroscopic) inflamed colonic mucosa and were compared with those of endoscopically non-inflamed colonic mucosa taken from the same 22 patients. In patients with Crohn's disease, the colonic IL-8 mRNA expression, which was determined as a standard inflammatory marker, was 5.9-fold higher in the inflamed biopsy samples compared with uninflamed biopsies (p,0.05; table 2).
Similarly, we measured increased IL-26 mRNA expression in inflamed colonic biopsies compared with non-inflamed colonic tissue (increase between 1.1-and 15.0-fold; table 2). The increases in IL-8 and IL-26 expression in inflamed biopsies were (table 2) .
A preliminary study of Th17 cells from healthy donors differentiated from peripheral T cells in vitro suggested Th17 cells as the source of IL-26 production. 4 To clarify if colonic Th17 cells express IL-26 in situ, we performed co-staining using specific antibodies directed against IL-26 and RORct, a transcription factor that is specifically expressed in Th17 cells. 7 The current medical therapy and the anatomic site, from which the samples were taken, are given for all patients. Biopsy sampling for inflamed and non-inflamed lesions was aimed to be taken in the same colonic or ileal segment. This was not possible in patients marked with an asterisk due to severe inflammation in the whole anatomic segment. Therefore, biopsies from a bordering (non-inflamed) segment were included for comparison. AZA, azathioprine; F, female; IFX, infliximab; M, male; 6-MP, 6-mercaptopurine; MTX, methotrexate; ND, not determined 16 and IL-31. 22 In contrast, cell lines such as HepG2, which do not express the IL-20R1 subunit, are not responsive to IL-26 treatment.
Examples of this immunohistochemical analysis shown in fig 7
Intestinal inflammation
It has been shown that activated T cells are a major source of IL-26 production. 1 3 Depending on the T cell source of cytokine production, cytokines have been differentiated in Th1 and Th2 cytokines. Previous studies demonstrated an induction of IL-26 production particularly in Th1 cells. 3 Crohn's disease is considered to represent a Th1-and Th17-mediated intestinal inflammation, while ulcerative colitis has, at least to some degree, features of Th2-mediated colitis. 28 29 Consistent with this observation, in our study the relative upregulation of IL-26 expression (compared with uninflamed tissue) was more pronounced in inflamed lesions of patients with Crohn's disease compared with patients with ulcerative colitis. Moreover, colonic IL-26 mRNA expression correlated strongly with IL-8 and IL-22 mRNA expression, confirming IL-26 as a marker of intestinal inflammation.
Our detailed immunohistochemical analysis revealed for the first time IL-26 protein expression in situ. There was an increased number of IL-26-expressing cells in active Crohn's disease which correlated with the results of our quantitative PCR analysis of colonic biopsy tissue taken from inflamed and uninflamed mucosa affected by Crohn's disease. IL-26 expression was found in infiltrating intestinal T cells including RORct-expressing Th17 cells, but not in primary IECs. This is of particular interest, since very recent evidence suggests that Th17 cells contribute to the pathogenesis of IBD, particularly Crohn's disease. 28 This is also supported by a recent genomewide association study demonstrating IL23R, which is expressed by Th17 cells, to be a Crohn's disease susceptibility gene. 30 We recently confirmed IL23R as an IBD susceptibility gene in the German population. 31 Interestingly, we demonstrated that the genetic risk for Crohn's disease mediated by IL23R is directly linked to the expression of the proinflammatory cytokine IL-22 32 which is also expressed in Th17 cells. 4 Moreover, we and others demonstrated an increased expression of Th17 cytokines and chemokines such as IL-17A, IL-17F, IL-22 and CCL20 in active Crohn's disease. 16 32-35 Here, we show significantly increased IL-26 serum levels in patients with Crohn's disease compared with healthy controls. However, overall IL-26 serum levels were rather low, which is probably related to the fact that only less than 1% of cells in the peripheral blood are Th17 cells. 36 In contrast, the high number of infiltrating RORct-expressing intestinal Th17 cells in active Crohn's disease suggests an important role for this cell type in local tissue inflammation. IL-26-producing Th17 cells are likely to sustain intestinal inflammation since we demonstrate here that IL-26 upregulates the gene transcription of several proinflammatory cytokines such as IL-8 and TNFa in IECs, while its own expression is upregulated in IBD. A recent study demonstrated that peripheral T cells, which differentiated under the influence of IL-23 and IL-1b to Th17 cells, produce IL-26, supporting Th17 cells as a major source of IL-26 production. 4 In contrast, IL-23 is mainly produced in ileal dendritic cells. 37 We and others recently demonstrated that ileal dendritic cells play a major role in the luminal sampling of bacterial pathogens, 38 thereby potentially linking defects in the antibacterial defence with the pathogenesis of Crohn's disease.
In addition, we demonstrate that IL-26 is functional in IECs. IL-26-induced STAT1/3 activation results in increased SOCS-3 mRNA expression. This confirms our previous studies demonstrating that SOCS-3 is an immediate early transcriptional target of STAT1/3. 16 27 Interestingly, in Crohn's disease, increased colonic STAT1 phosphorylation and SOCS-3 protein levels were found, 39 supporting our findings of a proinflammatory role for IL-26 in Crohn's disease. Another study demonstrated in a murine colitis model that SOCS-3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. 40 In addition, we recently showed that signalling of other IL-10-like cytokines such as IL-22 and the IFNls IL-28A and IL-29 is abrogated by increased expression of SOCS proteins in hepatic cell lines 18 19 41 and neuroendocrine cells. 26 This suggests that IL-10-like cytokines increase the expression of SOCS-3 and proinflammatory cytokines, while in turn SOCS-3 has a negative feedback on the expression and signalling of these cytokines. Interestingly, we found a similar mechanism for the signalling mediated by IFNa 42 and IFNb. 43 Moreover, similar to the results of our studies with IL-28A and IL-29, 17 26 44 45 two other IL-10-related cytokines, IL-26 mediates antiproliferative effects in IECs.
In summary, this is the first report on the role of IL-26 in human disease, particularly IBD. Here, we demonstrate that IECs express the functional IL-26 receptor complex. IL-26 activates STAT1/3, Akt, ERK and SAPK/JNK MAP kinases and upregulates the expression of proinflammatory cytokines and of SOCS-3 mRNA. In addition, IL-26 mRNA expression is upregulated in inflamed colonic lesions of patients with Crohn's disease due to an increased infiltration of IL-26-expressing immune cells including RORct-expressing Th17 cells. Colonic IL-26 expression in IBD correlates highly with the expression of IL-22, another Th17 cytokine. However, the functional analysis of IL-26, particularly in murine models of intestinal inflammation, is limited by the fact that the IL-26 gene is not expressed in mice. In conclusion, our data indicate a role for this novel cytokine system in promoting proinflammatory gene transcription, suggesting a role in intestinal inflammation. Considering the recent progress in IBD genetics and the identification of IL23R as an IBD susceptibility gene 30 31 and of IL26 as a susceptibility gene for ulcerative colitis, 46 IL-26 is probably an important effector cytokine by which Th17 cells contribute to the pathogenesis of IBD.
Robin Spiller, Editor
Atypical dyspepsia
CLINICAL PRESENTATION
A 68-year-old man with a history of dyspepsia and hiatus hernia presented with 15 kg weight loss with occasional nausea and vomiting episodes over the previous year. He was not taking any regular medication. He underwent gastroscopy, colonoscopy and barium swallow 1 year earlier to investigate change in bowel habit and dyspepsia. These tests revealed hiatus hernia and a non-specific motility disorder of the distal oesophageal segment. Clinical examination was unremarkable. Blood tests were all normal. An ultrasound scan of the abdomen was normal and repeat gastroscopy again showed only hiatus hernia. A chest x ray, which was performed in view of weight loss and smoking history, was normal.
Symptoms initially improved with regular domperidone; however, vomiting became more frequent and occurred in association with abdominal pain.
A repeat ultrasound scan of the abdomen was arranged (fig 1) .
QUESTION
What is the diagnosis?
See page 1288 for the answer.
